Urologic Neoplasms

• 

  Subject Areas on Research

  • A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. 
  • A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. 
  • A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. 
  • Advanced topics in evidence-based urological oncology: using results of a subgroup analysis. 
  • Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). 
  • Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). 
  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. 
  • Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. 
  • Complications of laparoscopic surgery for urological cancer: a single institution analysis. 
  • Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. 
  • Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States? 
  • Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. 
  • Episode-based Payment Variation for Urologic Cancer Surgery. 
  • Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. 
  • Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX8 immunohistochemistry. 
  • Gene therapy in urologic oncology. 
  • Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. 
  • Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers. 
  • High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis. 
  • Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. 
  • Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. 
  • Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. 
  • Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. 
  • Letter to the Editor: mRNA Vaccines in Urological Malignancies. 
  • Low-power holmium laser for the management of urinary tract calculi, structures, and tumors. 
  • Managing female sexual dysfunction. 
  • Microhematuria in Postmenopausal Women: Adherence to Guidelines in a Tertiary Care Setting. 
  • Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. 
  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. 
  • Open versus laparoscopic nephroureterectomy: is there really a debate? 
  • Origin, Incidence, and Management of Nongynecologic Pelvic Masses Seen on Cross-sectional Imaging. 
  • Outcomes of ureteroscopy. 
  • Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). 
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. 
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. 
  • Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). 
  • Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. 
  • Robotic surgery in urological oncology: patient care or market share? 
  • Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. 
  • Special applications of flexible deflectable ureterorenoscopy. 
  • The Role of Opioids and Their Receptors in Urological Malignancy: A Review. 
  • The association of oncogenic human papillomaviruses with urologic malignancy. The controversies and clinical implications. 
  • Urachal anomalies: a longitudinal study of urachal remnants in children and adults. 
  • Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. 
• 

  Keywords of People

  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Inman, Brant Allen, Professor of Surgery, Surgery, Urology
  • Routh, Jonathan Charles, Paul H. Sherman, M.D. Distinguished Associate Professor of Surgery, Pediatrics